Recruiting

Testing a new pill combined with immunotherapy drugs for advanced cancer

Plain-English translation of NCT06362369 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated June 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This clinical trial is testing a new medication called (also called 7HP349) when given together with two immunotherapy drugs called and . The study wants to find the right dose of and learn whether this combination is safe and helps patients with advanced cancers that have spread or cannot be surgically removed.

Current immunotherapy treatments don't work for everyone with advanced cancer, and researchers hope that combining this new medication with existing immunotherapies might help more patients respond to treatment and improve outcomes.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with advanced or metastatic cancer (such as melanoma, lung cancer, kidney cancer, colorectal cancer, or liver cancer) that has not responded to or has returned after at least one prior treatment
you have adequate blood cell counts, kidney function, and liver function as measured by blood tests
you are able to care for yourself with little or no help (ECOG performance status 0 or 1)
you have a life expectancy of at least 12 weeks
you are willing to use contraception during and after treatment if you are able to have children

You likely don't qualify if…

you have received cancer treatment or radiation within the past 3 weeks, or major surgery within the past 4 weeks
you have active cancer that has spread to your brain or around your spinal cord
you have had severe immune-related side effects (Grade 3 or higher) from prior immunotherapy treatments such as severe inflammation of the colon, lungs, or skin
you are currently taking other anticancer medications or biologics without appropriate washout time

What participation looks like

You will take the new pill by mouth for one cycle, then continue taking it for 4 cycles while also receiving infusions. After that, you'll stop the new medication and continue with infusions alone for 11 additional cycles, with the entire treatment lasting about 12 months. You'll have regular blood tests, scans, and clinic visits to monitor how the treatment is working and watch for any side effects.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Trial locations(5 sites)

United States

University of Colorado Cancer Center, Aurora, Colorado

Florida Cancer Specialists, Lake Mary, Florida

Dartmouth Hitchcock, Lebanon, New Hampshire

Brown University Health Cancer Institute, Providence, Rhode Island

MD Anderson Cancer Center, Houston, Texas